title: Major response to everolimus in melanoma with acquired imatinib resistance.
authors.affiliation: Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Si
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Xu
authors.forename: Yan
authors.initials: Y
authors.lastname: Kong
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Chi
authors.forename: Chuanliang
authors.initials: C
authors.lastname: Cui
authors.forename: Xinan
authors.initials: X
authors.lastname: Sheng
authors.forename: Siming
authors.initials: S
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Dai
authors.forename: Weiwei
authors.initials: W
authors.lastname: Yu
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
mesh_terms: D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D000068338:Everolimus; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000068338:Everolimus; D020123:Sirolimus